{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T15:04:46Z","timestamp":1770563086353,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2007,1,18]],"date-time":"2007-01-18T00:00:00Z","timestamp":1169078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,1,18]],"date-time":"2007-01-18T00:00:00Z","timestamp":1169078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/s00296-006-0272-7","type":"journal-article","created":{"date-parts":[[2007,1,17]],"date-time":"2007-01-17T11:52:43Z","timestamp":1169034763000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-\u03b1 blocker plus methotrexate versus methotrexate or leflunomide alone"],"prefix":"10.1007","volume":"27","author":[{"given":"Margaret","family":"Wis\u0142owska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danuta","family":"Jakubicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,1,18]]},"reference":[{"key":"272_CR1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/ard.2005.044560","volume":"64","author":"JA Harbin","year":"2005","unstructured":"Harbin JA (2005) Dendritic cells: potential triggers of autoimmunity and targets for therapy. Ann Rheum Dis 64:86\u201390","journal-title":"Ann Rheum Dis"},{"key":"272_CR2","unstructured":"Firestein GS (2001) Etiology and pathogenesis of rheumatoid arthritis. In: Kelley\u2019s textbook of rheumatology, 6th edn, pp 921\u2013964"},{"key":"272_CR3","unstructured":"Harris ED (2001) Treatment of rheumatoid arthritis. In: Kelley\u2019s textbook of rheumatology, 6th edn, pp 1001\u20131022"},{"key":"272_CR4","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1136\/ard.2005.039339","volume":"64","author":"S Irvine","year":"2005","unstructured":"Irvine S, Capell HC (2005) Great expectations of modern RA treatment. Ann Rheum Dis 64:1249\u20131251","journal-title":"Ann Rheum Dis"},{"key":"272_CR5","first-page":"102","volume":"5","author":"Natalizumab","year":"2004","unstructured":"Natalizumab (2004) AN 100226, anti-4alpha integrin monoclonal antibody. Drugs 5:102\u2013107","journal-title":"Drugs"},{"key":"272_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/03009740410005467","volume":"33","author":"R Rau","year":"2004","unstructured":"Rau R, Simianer S, van Riel PL et al (2004) Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab In combination with methotrexate. Scand J Rheumatol 33:145\u2013153","journal-title":"Scand J Rheumatol"},{"key":"272_CR7","doi-asserted-by":"crossref","unstructured":"American college of rheumatology subcommittee on rheumatoid arthritis guidelines: guidelines for the management of rheumatoid arthritis 2002 update. (2002) Arthritis Rheum 16:328\u2013346","DOI":"10.1002\/art.10148"},{"key":"272_CR8","unstructured":"Stein CM (2001) Immunoregulatory drugs. In: Kelley\u2019s textbook of rheumatology, 6th edn, pp 879\u2013898"},{"key":"272_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/ar1157","volume":"6","author":"G Palmer","year":"2004","unstructured":"Palmer G, Burger D, Merin F (2004) The active metabolite of leflunomide: A77 1726 increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 6:181\u2013189","journal-title":"Arthritis Res Ther"},{"key":"272_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Block DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"272_CR11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jama.1949.02900430001001","volume":"140","author":"O Steinbrocker","year":"1949","unstructured":"Steinbrocker O, Treger H, Cornelius H (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659\u2013661","journal-title":"JAMA"},{"key":"272_CR12","first-page":"189","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz PW Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scale. J Rheumatol 9:189\u2013196","journal-title":"J Rheumatol"},{"key":"272_CR13","unstructured":"Rau R (2000) Methotrexate. Rheumatoid arthritis. New frontiers in pathogenesis and treatment. Oxford University Press, New York, pp 337\u2013350"},{"key":"272_CR14","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::AID-ART6>3.0.CO;2-M","volume":"41","author":"DT Felson","year":"1998","unstructured":"Felson DT, Andersen JJ, Lance ML et al (1998) Should improvement in rheumatoid arthritis clinical trials be defined by fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41:1564\u20131570","journal-title":"Arthritis Rheum"},{"key":"272_CR15","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2249.2004.02555.x","volume":"137","author":"K Migita","year":"2004","unstructured":"Migita K, Migashita T, Ishibashi H et al (2004) Suppressive effect of leflunomide metabolite (A77 1726) on metaloproteinase production in IL-1 beta stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol 137:612\u2013616","journal-title":"Clin Exp Immunol"},{"key":"272_CR16","first-page":"1725","volume":"30","author":"F Wolfe","year":"2003","unstructured":"Wolfe F, Michaud K, Stephenson B, Doyle J (2003) Toward a definision and metod of assessment of treatment failure and effectiveness: the case of leflunomid versus Methotrexate. J Rheumatol 30:1725\u20131732","journal-title":"J Rheumatol"},{"key":"272_CR17","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","volume":"159","author":"V Strand","year":"1999","unstructured":"Strand V, Cohen S, Schiff M et al (1999) Treatment of active rheumatoid arthritis with leflunomid compared with placebo and methotrexate. Arch Intern Med 159:2542\u20132550","journal-title":"Arch Intern Med"},{"key":"272_CR18","unstructured":"Arava (2003) Prescribing information of September 2003, Aventis Pharmaceuticals"},{"key":"272_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675\u2013681","journal-title":"Lancet"},{"key":"272_CR20","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"JM Kremer","year":"2005","unstructured":"Kremer JM, Dougados M Emery P et al (2005) Treatment of rheumatoid arthritis with the selective co-stimulation modulator abatacept: twelve-month results of a phase iib, double blind, randomised, placebo-controlled trial. Arthritis Rheum 52:2263\u20132271","journal-title":"Arthritis Rheum"},{"key":"272_CR21","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"RN Maini","year":"1999","unstructured":"Maini RN, St Clair EW, Breedvelt F et al (1999) Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"272_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1517\/14712598.5.5.683","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Nishimoto N, Ohsugi Y (2005) The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 5:683\u2013690","journal-title":"Expert Opin Biol Ther"},{"key":"272_CR23","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/01.bor.0000159927.19891.eb","volume":"17","author":"L Pollard","year":"2005","unstructured":"Pollard L, Choy E (2005) Rheumatoid arthritis: non-tumour necrosis factor targets. Curr Opin Rheumatol 17:242\u2013246","journal-title":"Curr Opin Rheumatol"},{"key":"272_CR24","unstructured":"van Riel PLCM, Kroot EJJA (1998) Gold, antimalarials and other DMARDs. In: Kelley\u2019s Textbook of Rheumatology, 5th edn, pp 351\u2013360"},{"key":"272_CR25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliot","year":"1993","unstructured":"Elliot MJ, Maini RN, Feldman M et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681\u20131889","journal-title":"Arthritis Rheum"},{"key":"272_CR26","unstructured":"Blumenauer B, Judd M, Cranney A et al (20030 Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 4:CD004525"},{"key":"272_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/art.10084","volume":"46","author":"RJ Reece","year":"2002","unstructured":"Reece RJ, Kraan MC, Radjenovic A et al (2002) Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 46:366\u2013372","journal-title":"Arthritis Rheum"},{"key":"272_CR28","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/ard.59.7.504","volume":"59","author":"JS Smolen","year":"2000","unstructured":"Smolen JS, Breedvelt FC, Burmester GR et al (2000) Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 59:504\u2013505","journal-title":"Ann Rheum Dis"},{"issue":"71","key":"272_CR29","first-page":"13","volume":"31","author":"JS Smolen","year":"2004","unstructured":"Smolen JS, Emery P, Kalden JR et al (2004) The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol 31(71):13\u201320","journal-title":"J Rheumatol"},{"key":"272_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2005.042549","volume":"64","author":"JJ Cush","year":"2005","unstructured":"Cush JJ (2005) Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 64:18\u201323","journal-title":"Ann Rheum Dis"},{"key":"272_CR31","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/berh.1999.0056","volume":"13","author":"A Tyndall","year":"1999","unstructured":"Tyndall A, Millikan S (1999) Bone marrow transplantation. Bailliere\u2019s Clin Rheumatol 13:719\u2013735","journal-title":"Bailliere\u2019s Clin Rheumatol"},{"key":"272_CR32","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.1780351003","volume":"35","author":"DT Felson","year":"1992","unstructured":"Felson DT, Andersen JJ, Meenen RJ (1992) Use of short-term efficacy\/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 35:1117\u20131125","journal-title":"Arthritis Rheum"},{"key":"272_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U","volume":"43","author":"JT Sharp","year":"2000","unstructured":"Sharp JT, Strand V, Leung H et al (2000) treatment weith leflunomide slows radiographic progression of rheumatoid arthritis: results of three randomised controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 43:495\u2013505","journal-title":"Arthritis Rheum"},{"key":"272_CR34","unstructured":"Wollheim FA (1998) Rheumatoid arthritis\u2014the clinical picture. In: Oxford textbook of rheumatology. Oxford University Press, New York, pp 1004\u20131036"},{"key":"272_CR35","first-page":"647","volume":"29","author":"WJ Shergy","year":"2002","unstructured":"Shergy WJ, Isern RA, Cooley DA et al (2002) Open label study to assess infliximab safety and timing of onset of clinical benefits among patients with rheumatoid arthritis. J Rheumatol 29:647\u2013649","journal-title":"J Rheumatol"},{"key":"272_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1186\/ar1727","volume":"7","author":"BM Kirsch","year":"2005","unstructured":"Kirsch BM, Zeyda M, Stuhmaier K et al (2005) The active metabolite of leflunomide A77 1726 interferes with dendritic cell function. Arthritis Res Ther 7:694\u2013703","journal-title":"Arthritis Res Ther"},{"key":"272_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein in patients in rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"key":"272_CR38","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2165\/00003495-200262170-00012","volume":"62","author":"CR Culy","year":"2002","unstructured":"Culy CR, Keating GM (2002) Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493\u20132537","journal-title":"Drugs"},{"key":"272_CR39","first-page":"618","volume":"103","author":"JL Lan","year":"2004","unstructured":"Lan JL, Chou SJ, Chen DY et al (2004) A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis at 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 103:618\u2013623","journal-title":"J Formos Med Assoc"},{"key":"272_CR40","unstructured":"Maini RN, Feldmann M (2001) Immunopathogenesis of rheumatoid arthritis. In: Kelley\u2019s textbook of rheumatology, 6th edn, pp 983\u20131002"},{"key":"272_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant metotrexate: the ARMADA trial. Arthritis Rheum 48:35\u201345","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0272-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-006-0272-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0272-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-006-0272-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T01:17:39Z","timestamp":1736731059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-006-0272-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,18]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["272"],"URL":"https:\/\/doi.org\/10.1007\/s00296-006-0272-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,18]]},"assertion":[{"value":"18 August 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}